2seventy Bio reports Q4 EPS (37c) vs ($1.11) last year

Written by Emily J. Thompson, Senior Investment Analyst

TSVT%

Updated: Mar 25 2025

0mins

Q4 Revenue Performance: 2seventy bio reported a Q4 revenue of $2.9 million, significantly lower than the consensus estimate of $13.03 million.
Focus on Abecma Therapy: CEO Chip Baird emphasized the company's commitment to streamlining operations and focusing on Abecma, the first FDA-approved CAR T cell therapy for multiple myeloma, in collaboration with BMS to improve patient outcomes.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

2seventy Bio reports Q4 EPS (37c) vs ($1.11) last year

About the author

Top News

Oil Firms Cautious on Venezuela Investment Push

GM Reports $7.1 Billion Charge Amid EV Shift

Stock Market Wraps 2025 with Double-Digit Gains

Novo Nordisk's Weight-Loss Pill Approval: Key Impacts

Related Articles

Kenvue's Study Finds No Autism Link with Acetaminophen Use During Pregnancy

Microsoft Holds 27% Stake in OpenAI Worth $203 Billion

Sigh Up to Get Intellectia Insights

How did the company's recent strategic decisions impact its latest financial performance?

Can you explain the factors behind the recent changes in the company's stock price?

What are the expected impacts of current market trends on the company's future growth?

Based on the latest earnings report, what are the company's forecasted revenues for the next quarter?

How does the company's performance compare to its main competitors in the same sector?

People Also Watch